FDA approved a supplemental New Drug Application for BALVERSA® for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma.
Johnson & Johnson announced that FDA approved a supplemental New Drug Application (sNDA) for BALVERSA® (erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations…